Emtricitabine
Established medicineAlso known as (-)-FTC, Atripla, Biktarvy, Complera+17 more
(-)-FTC, Atripla, Biktarvy, Complera, Descovy, Emtriva, FTC, Genvoya, Odefsey, Stribild, Symtuza, Truvada, Emtricitabin, Emtricitabina, (+/-)-Emtricitabine, (-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one, (2R-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone, 4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one, 5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine, Emtricitabine, (+/-)-, Emtricitabinum.
Recent clinical, regulatory, research and industry developments relating to this drug.
STAT+: Hims misled consumers and violated their privacy, FTC alleges in a lawsuit
FTC, four state AGs sue transgender health group over care standards
Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
Label change: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (ANDA091055)
Label change: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (ANDA091055)
Approval: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (ANDA091055)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Emtriva is indicated for the treatment of HIV-1 infected adults and children in combination with other antiretroviral agents. This indication is based on studies in… Show full indicationShow less
Emtriva is indicated for the treatment of HIV-1 infected adults and children in combination with other antiretroviral agents. This indication is based on studies in treatment-naive patients and treatment-experienced patients with stable virological control. There is no experience of the use of Emtriva in patients who are failing their current regimen or who have failed multiple regimens. When deciding on a new regimen for patients who have failed an antiretroviral regimen, careful consideration should be given to the patterns of mutations associated with different medicinal products and the treatment history of the individual patient. Where available, resistance testing may be appropriate.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.